EXAS / Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption. more_horizontal

Many investors are probably upset that the yields of the 10-year treasury bonds are trading around 5%. It's true that higher bond yields do increases more_horizontal

At the end of September, Cathie Wood sat down with Morningstar to discuss the current and future state of Ark Invest, including the investment managem more_horizontal

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency. more_horizontal

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today a more_horizontal

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, t more_horizontal

Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences' shares are up more than 31% more_horizontal

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need. more_horizontal